# Source note — Rachel Rubin / sexual medicine / GSM / vaginal estrogen

Date: 2026-06-22  
Managing Expectations Health source-check / deep report

## Original media source

- URL: https://www.youtube.com/watch?v=MM-Qhlxf1pM
- Shared short URL: https://youtu.be/MM-Qhlxf1pM?si=D_eVJCMjPCP-lqK5
- Title from YouTube oEmbed: `Intimacy Expert: The Masterclass On Better Sex, Orgasms & Pleasure | Dr Rachel Rubin`
- Channel: The Diary Of A CEO
- Transcript captured locally: `rachel-rubin-sexual-medicine-gsm-vaginal-estrogen-youtube-transcript-2026-06-22.txt`
- Metadata captured locally: `rachel-rubin-sexual-medicine-gsm-vaginal-estrogen-youtube-metadata-2026-06-22.json`
- Transcript length: 1:48:00, 3,356 segments in fetched transcript.

## Speaker / profile checked

- Dr. Rachel Rubin official site: https://www.rachelrubinmd.com/
- About page: https://www.rachelrubinmd.com/about
- Official profile says her practice is a nationally recognized urology and sexual medicine practice seeing patients of all genders for sexual function, desire, arousal, orgasm, pain, erectile dysfunction, urinary tract/vaginal infections, incontinence, prolapse, perimenopause and menopause symptoms.
- Her about page states she was involved in development/release of AUA medical guidelines for Genitourinary Syndrome of Menopause (GSM).

## Core claims extracted from transcript

### Vaginal estrogen / vaginal hormones

At the beginning and around 34–39 minutes, the video argues that vaginal estrogen/vaginal DHEA can:

- reduce painful/dry sex;
- help arousal and orgasm;
- reduce urinary frequency, urgency, leakage;
- reduce recurrent urinary tract infections;
- be underprescribed;
- be safer than many patients and clinicians believe.

Representative transcript window:

> 34:49–35:07: “rub it in like you would rub sunscreen on your face ... if you do that twice a week you can prevent death from urinary tract infections. You can help with urinary frequency, urinary urgency, leakage, you make sex not painful and dry, it helps with arousal and orgasm. It’s literally better than Viagra...”

> 38:24–38:31: “vaginal hormones, vaginal estrogen or vaginal DHEA ... prevent UTIs by more than half.”

Editorial caution: the direction of the claim is guideline-consistent for GSM and recurrent UTI prevention in peri/postmenopausal or hypoestrogenic patients, but phrases such as “better than Viagra,” “safe for everybody on Earth,” and “prevent death” are advocacy language and should be translated into guideline language for public health reporting.

### Orgasm gap / sex education

At 0:41–1:09, the video argues women orgasm less often than men, many women think orgasm should come from penetration, and most orgasm physiology is clitoral. The article should treat this as sexual-health education rather than scandal language.

### Menopause / hormone therapy / medical education gap

At 3:39–4:37, Rubin argues that affluent public figures still had trouble getting appropriate menopause/perimenopause care and that menopause/hormonal/sexual-health education is not sufficiently taught in medical training. This is consistent with the broader theme of underdiagnosis/undertreatment, but individual celebrity examples should be presented as illustrative claims, not clinical data.

### Testosterone / libido

Around 12:24–13:22, Rubin emphasizes that women produce testosterone and that it should not be considered only a “male hormone.” Evidence supports systemic testosterone for carefully assessed postmenopausal women with hypoactive sexual desire disorder (HSDD), but not broad wellness/anti-aging use.

### Pain with sex / pelvic floor / multimodal care

Around 48:07–49:04 and 52:49–53:33, Rubin discusses multiple causes of vulvar/vaginal pain: hormonal tissue changes, skin disease, pelvic floor muscle dysfunction, nerves/spine, endometriosis/scarring. This aligns with a biopsychosocial / multidisciplinary sexual-medicine model.

## Guideline and evidence anchors

### AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause (2025)

- URL: https://www.auanet.org/guidelines-and-quality/guidelines/genitourinary-syndrome-of-menopause
- The guideline says clinicians should offer local low-dose vaginal estrogen to patients with GSM to improve vulvovaginal discomfort/irritation, dryness and/or dyspareunia.
- It says clinicians should recommend local low-dose vaginal estrogen for GSM patients with recurrent UTIs to reduce future UTI risk.
- It supports lubricants/moisturizers and avoiding irritants.
- It says evidence does not support alternative supplements for GSM.
- It says evidence does not support CO2 laser, Er:YAG laser, or radiofrequency for several GSM outcomes; lasers may be considered experimental outside trials in shared decision-making.
- It says patients with breast-cancer history may use local low-dose vaginal estrogen in multidisciplinary shared decision-making.

### ACOG — urogenital symptoms in breast-cancer survivors

- URL: https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2021/12/treatment-of-urogenital-symptoms-in-individuals-with-a-history-of-estrogen-dependent-breast-cancer
- ACOG says nonhormonal methods should be considered first-line for urogenital symptoms in individuals with a history of estrogen-dependent breast cancer.
- If nonhormonal treatments fail, low-dose vaginal estrogen may be used after risk-benefit discussion, including for tamoxifen users; for aromatase-inhibitor users, shared decision-making should include the patient, gynecologist and oncologist.

### NCBI / StatPearls overview of GSM

- URL: https://www.ncbi.nlm.nih.gov/books/NBK559297/
- GSM is a hypoestrogenic condition affecting vulvovaginal, urinary and sexual health.
- Common symptoms include dryness, irritation, burning, dyspareunia, recurrent UTIs and urinary incontinence/urgency.
- GSM is common, progressive and underdiscussed.
- Treatment options include lubricants/moisturizers, local vaginal estrogen, vaginal DHEA, systemic hormone therapy when systemic symptoms exist, ospemifene, pelvic-floor PT/dilators in selected cases.

### PubMed evidence checked

- PMID 32564121 — Estrogen for prevention of recurrent UTIs in postmenopausal women: meta-analysis of randomized controlled trials. Abstract reports vaginal estrogen significantly reduced recurrent UTI; oral estrogen did not.
- PMID 30562320 — Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Long observational follow-up evaluating cardiovascular disease, cancer and hip fracture outcomes in vaginal estrogen users not using systemic hormone therapy.
- PMID 40298120 / 41026118 — 2025 AUA/SUFU/AUGS GSM guideline and executive summary.
- PMID 33814355 / 33797277 / 33792440 — ISSWSH clinical practice guideline for systemic testosterone for HSDD in women.
- PMID 31498871 / 31488288 — Global Consensus Position Statement on testosterone therapy for women; supported indication is HSDD in postmenopausal women, not generalized wellness use.
- PMID 39207435 — Scoping review of the gender gap in partnered orgasm; women’s orgasm rates increase with clitoral stimulation and social/partner factors matter.
- PMID 37720816 — Female sexual medicine content in medical curricula; supports educational gap theme.
- Pelvic floor / dyspareunia evidence: recent systematic-review literature supports pelvic floor and physiotherapy approaches for selected women, though protocols and evidence quality vary by condition.

## Similar clinicians/public voices compared

- Rachel Rubin, MD — urologist/sexual medicine; strong focus on GSM, low-dose vaginal estrogen, sex education, orgasm, urinary health, clinician training gaps.
- Kelly Casperson, MD — board-certified urologist and public educator on sexuality and hormones; similar urology/sexual-medicine advocacy tone.
- Lauren Streicher, MD — menopause and sexual medicine public educator; focuses on menopause, vaginal health, sexual function and clinical education.
- Mary Claire Haver, MD — OB/GYN and menopause educator; broader lifestyle/metabolic/menopause brand, more wellness-facing.
- Louise Newson, MD — UK menopause/hormone educator; strong public advocacy for menopause recognition and HRT access.
- Jen Gunter, MD — OB/GYN science communicator; often more skeptical/debunking-oriented, emphasizes evidence and pushes back against wellness overreach.

## Evidence labels for final article

Supported / mainstream:
- GSM is real, common, underdiscussed and treatable.
- Local low-dose vaginal estrogen is guideline-supported for GSM symptoms and recurrent UTIs in appropriate hypoestrogenic patients.
- Vaginal moisturizers/lubricants are useful first-line/adjuncts.
- Pelvic floor dysfunction and pain with sex require assessment; pelvic-floor PT may help selected patients.
- Testosterone has a narrow evidence-supported role for postmenopausal HSDD after biopsychosocial assessment and monitoring.

Needs nuance:
- “Safe for everybody” overstates; breast-cancer survivors, unexplained bleeding and complex histories need shared decision-making.
- “Better than Viagra” is advocacy framing, not a direct equivalence claim across drugs/conditions.
- “Prevents death from UTIs” may be directionally related to preventing recurrent UTIs in older adults but should not be presented as a mortality-proven endpoint for all patients.
- Menopause/HRT debates require separating local vaginal estrogen from systemic hormone therapy.

Reader-protection frame:
- Do not start hormones, testosterone, DHEA, ospemifene or compounded products from a podcast alone.
- Ask a qualified clinician about GSM, recurrent UTIs, painful sex, bleeding, cancer history, clot/stroke history, medications and individual risk.
- If symptoms include postmenopausal bleeding, new pelvic pain, fever/flank pain, persistent UTI symptoms, or concern for STI/trauma, seek medical evaluation promptly.